CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRVO CervoMed

Post-Market Trading 03-31 16:20:28 EDT

9.15

-0.33

-3.48%

盘后9.00

-0.15-1.64%

16:13 EDT

High10.07	Low8.75	Vol592.81K
Open9.46	D1 Closing9.48	Amplitude13.92%
Mkt Cap79.63M	Tradable Cap48.94M	Total Shares8.70M
T/O5.53M	T/O Rate11.08%	Tradable Shares5.35M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"CRVO","market":"US","secType":"STK","nameCN":"CervoMed","latestPrice":9.15,"timestamp":1743451200000,"preClose":9.48,"halted":0,"volume":592806,"hourTrading":{"tag":"盘后","latestPrice":9,"preClose":9.15,"latestTime":"16:13 EDT","volume":10876,"amount":98633.780564,"timestamp":1743451984637},"delay":0,"floatShares":5348500,"shares":8702719,"eps":-2.017884,"marketStatus":"Post-Market Trading","change":-0.33,"latestTime":"03-31 16:20:28 EDT","open":9.46,"high":10.07,"low":8.75,"amount":5532007.119431,"amplitude":0.139241,"askPrice":9.25,"askSize":50,"bidPrice":8.8,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-2.017884,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1743465600000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":9.48,"preHourTrading":{"tag":"盘前","latestPrice":9.448,"preClose":9.48,"latestTime":"09:29 EDT","volume":17390,"amount":164207.21396999998,"timestamp":1743427773235},"postHourTrading":{"tag":"盘后","latestPrice":9,"preClose":9.15,"latestTime":"16:13 EDT","volume":10876,"amount":98633.780564,"timestamp":1743451984637},"volumeRatio":0.255698},"requestUrl":"/m/hq/s/CRVO","defaultTab":"news","newsList":[{"id":"2522765948","title":"CervoMed Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2522765948","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522765948?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 19:35","pubTimestamp":1742988900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2025 07:35 ET (11:35 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"gpt_icon":0},{"id":"2522022552","title":"CervoMed Announces Oral Presentation at 19TH International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/Pd™)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522022552","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522022552?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:00","pubTimestamp":1742904005,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nTUA7RRM5C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2522243022","title":"CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522243022","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522243022?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:00","pubTimestamp":1742904000,"startTime":"0","endTime":"0","summary":"BOSTON, March  25, 2025  (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/25/3048644/0/en/CervoMed-Announces-Oral-Presentation-at-19th-International-Conference-on-Alzheimer-s-and-Parkinson-s-Diseases-and-Related-Neurologic-Disorders-AP-PD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0345774391.USD","LU0205194284.USD","LU0348723411.USD","LU1169589451.USD","LU0240878834.USD","PD","CRVO","LU1169590202.USD","BK4097","LU0240877869.USD","DLB","BK4023","LU0205193047.USD","LU0345774631.USD"],"gpt_icon":0},{"id":"2520606218","title":"CervoMed Is Maintained at Buy by Roth MKM","url":"https://stock-news.laohu8.com/highlight/detail?id=2520606218","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520606218?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 22:36","pubTimestamp":1742308560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2025 10:36 ET (14:36 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"9bc4bc206e695fae65d16887a7636aa7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"gpt_icon":0},{"id":"2520624326","title":"CervoMed Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2520624326","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520624326?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 18:41","pubTimestamp":1742294494,"startTime":"0","endTime":"0","summary":"NasdaqCM:CRVO Earnings and Revenue History March 18th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 4.3%. Earnings per share  missed analyst estimates by 9.0%.Looking ahead, revenue is expected to decline by 1.9% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 20%.The company's shares are up 308% from a week ago.We don't want to rain on the parade too much, but we did also find 5 warning signs for CervoMed (3 don't sit too well with us!) that you need to be mindful of.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cervomed-full-2024-earnings-revenues-104134424.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRVO"],"gpt_icon":1},{"id":"2520982466","title":"Cervomed Inc. Faces Financial Hurdles Due to Regulatory Restrictions on Public Float","url":"https://stock-news.laohu8.com/highlight/detail?id=2520982466","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520982466?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 14:01","pubTimestamp":1742277701,"startTime":"0","endTime":"0","summary":"Cervomed Inc. (CRVO) has disclosed a new risk, in the Regulation category. Cervomed Inc. faces a significant financial risk due to certain regulato...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomed-inc-faces-financial-hurdles-due-to-regulatory-restrictions-on-public-float?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomed-inc-faces-financial-hurdles-due-to-regulatory-restrictions-on-public-float?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2520570140","title":"CervoMed Shares Rise After Positive Data From Neflamapimod Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2520570140","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520570140?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 00:59","pubTimestamp":1742230740,"startTime":"0","endTime":"0","summary":"CervoMed shares were up 28% to $8.27 after the company said it saw positive results from a Phase 2b trial for neflamapimod.The clinical-stage company on Monday said that, following \"highly encouraging\" 16-week extension results from the Phase 2b trial, it believes it has established proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies.The Boston-based company said it is now focusing on reporting the results from a 32-week extension phase in the second half of 2025, and on discussing next steps on Phase 3 trial design with regulatory authorities.Initial safety, biomarker and pharmacokinetic data from an ongoing trial in patients with a mild-to-moderate form of the disease, who are being treated with a twice-daily regimen of neflamapimod in the study, is expected to be available in the fourth quarter.CervoMed also said that as of Dec. 31 it had $38.9 million in cash, cash equivalents and marketable securities, compared with $7.8 million as of Dec. 31, ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"gpt_icon":1},{"id":"2520208925","title":"CervoMed Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2520208925","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520208925?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 22:04","pubTimestamp":1742220240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 17, 2025 10:04 ET (14:04 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"016d41f4580f6dca87db8a5e96195d68","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"gpt_icon":0},{"id":"2520540913","title":"CervoMed FY 2024 GAAP EPS $(2.02) Misses $(1.81) Estimate, Sales $9.738M Beat $9.537M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2520540913","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520540913?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 20:06","pubTimestamp":1742213174,"startTime":"0","endTime":"0","summary":"CervoMed (NASDAQ:CRVO) reported quarterly losses of $(2.02) per share which missed the analyst consensus estimate of $(1.81) by 11.6 percent. The company reported quarterly sales of $9.738 million which beat the analyst","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44354096/cervomed-fy-2024-gaap-eps-2-02-misses-1-81-estimate-sales-9-738m-beat-9-537m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"CervoMed FY 2024 GAAP EPS $(2.02) Misses $(1.81) Estimate, Sales $9.738M Beat $9.537M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"gpt_icon":0},{"id":"2520540669","title":"CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2520540669","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520540669?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 20:00","pubTimestamp":1742212800,"startTime":"0","endTime":"0","summary":"-Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), including improvement on the trial’s primary outcome mea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/17/3043647/0/en/CervoMed-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Corporate-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","LU0345774631.USD","LU0348723411.USD","LU0240877869.USD","CRVO","LU0205194284.USD","BK4139","LU0205193047.USD","LU0345774391.USD","LU0240878834.USD","DLB"],"gpt_icon":1},{"id":"2519397245","title":"Capital One, CervoMed, HPE, Eaton, PepsiCo: Trending by Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2519397245","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519397245?lang=en_us&edition=full_marsco","pubTime":"2025-03-15 17:01","pubTimestamp":1742029306,"startTime":"0","endTime":"0","summary":"Analysts are intrested in these 5 stocks: ( ($COF) ), ( ($CRVO) ), ( ($HPE) ), ( ($ETN) ) and ( ($PEP) ). Here is a breakdown of their recent","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/capital-one-cervomed-hpe-eaton-pepsico-trending-by-analysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/capital-one-cervomed-hpe-eaton-pepsico-trending-by-analysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COF","CRVO","HPE","PEP"],"gpt_icon":0},{"id":"2519856723","title":"BUZZ-CervoMed up after Jones Research upgrades rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2519856723","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519856723?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 23:48","pubTimestamp":1741880910,"startTime":"0","endTime":"0","summary":"BUZZ-CervoMed up after Jones Research upgrades rating** Shares of drug developer CervoMed CRVO.O rise 4.4% to $6.44** Brokerage Jones Research upgrades CRVO to \"buy\" rating from \"hold\", keeps PT of $15** Upgrade follows CRVO's announcement of positive results from study of its drug, neflamapimod, in patients with dementia with Lewy bodies  on Monday** Data from study is boosting investor confidence, and we are seeing a more riskon approach heading into the next steps for netlamapimod in DLB patients - Jones Research ** DLB is a form of dementia caused by the accumulation of protein deposits called Lewy bodies in the brain's nerve cells** Up to Wednesday's close, stock up 176.7% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nL4N3PW1A9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"gpt_icon":0},{"id":"2519485987","title":"CervoMed upgraded to Buy at JonesResearch on more confidence in DLB program","url":"https://stock-news.laohu8.com/highlight/detail?id=2519485987","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519485987?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 23:25","pubTimestamp":1741879536,"startTime":"0","endTime":"0","summary":"JonesResearch upgraded CervoMed (CRVO) to Buy from Hold with a $15 price target arguing that the company’s latest data from the open label extensio...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-upgraded-to-buy-at-jonesresearch-on-more-confidence-in-dlb-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-upgraded-to-buy-at-jonesresearch-on-more-confidence-in-dlb-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DLB","CRVO"],"gpt_icon":0},{"id":"2519855676","title":"CervoMed Inc : Jonestrading Raises to Buy From Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2519855676","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519855676?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 23:18","pubTimestamp":1741879134,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nFWN3PW19H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2519877388","title":"CervoMed Raised to Buy From Neutral by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2519877388","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519877388?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 19:02","pubTimestamp":1741863720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 13, 2025 07:02 ET (11:02 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"gpt_icon":0},{"id":"2519885556","title":"Chardan Upgrades CervoMed to Buy From Neutral, Price Target is $14","url":"https://stock-news.laohu8.com/highlight/detail?id=2519885556","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519885556?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 17:40","pubTimestamp":1741858841,"startTime":"0","endTime":"0","summary":"CervoMed (CRVO) has an average rating of overweight and mean price target of $25.57, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRVO"],"gpt_icon":0},{"id":"2518211027","title":"JonesTrading Sticks to Its Hold Rating for CervoMed (CRVO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2518211027","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518211027?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 23:55","pubTimestamp":1741708507,"startTime":"0","endTime":"0","summary":"In a report released today, Soumit Roy from JonesTrading maintained a Hold rating on CervoMed (CRVO – Research Report). The company’s shares opened...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-sticks-to-its-hold-rating-for-cervomed-crvo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-sticks-to-its-hold-rating-for-cervomed-crvo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"gpt_icon":0},{"id":"2518463657","title":"Brookline Capital Upgrades CervoMed to Buy From Hold, Price Target is $16","url":"https://stock-news.laohu8.com/highlight/detail?id=2518463657","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518463657?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 20:45","pubTimestamp":1741697137,"startTime":"0","endTime":"0","summary":"CervoMed (CRVO) has an average rating of overweight and mean price target of $35.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BRKL","CRVO"],"gpt_icon":0},{"id":"2518452597","title":"CervoMed price target raised to $15 from $7 at Roth MKM","url":"https://stock-news.laohu8.com/highlight/detail?id=2518452597","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518452597?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 20:32","pubTimestamp":1741696320,"startTime":"0","endTime":"0","summary":"Roth MKM analyst Boobalan Pachaiyappan raised the firm’s price target on CervoMed (CRVO) to $15 from $7 and keeps a Buy rating on the shares. The c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-price-target-raised-to-15-from-7-at-roth-mkm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-price-target-raised-to-15-from-7-at-roth-mkm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"gpt_icon":0},{"id":"2518898717","title":"CervoMed Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2518898717","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518898717?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 19:22","pubTimestamp":1741692120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 11, 2025 07:22 ET (11:22 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cervomed.com","stockEarnings":[{"period":"1week","weight":-0.3366},{"period":"1month","weight":3.2799},{"period":"3month","weight":2.95},{"period":"6month","weight":-0.3734},{"period":"1year","weight":-0.5931},{"period":"ytd","weight":3.0513}],"compareEarnings":[{"period":"1week","weight":-0.0148},{"period":"1month","weight":-0.0654},{"period":"3month","weight":-0.0661},{"period":"6month","weight":-0.0277},{"period":"1year","weight":0.0623},{"period":"ytd","weight":-0.0519}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.064666},{"month":2,"riseRate":0.555556,"avgChangeRate":0.120404},{"month":3,"riseRate":0.555556,"avgChangeRate":0.380037},{"month":4,"riseRate":0.375,"avgChangeRate":-0.070824},{"month":5,"riseRate":0.5,"avgChangeRate":0.190358},{"month":6,"riseRate":0.125,"avgChangeRate":-0.120544},{"month":7,"riseRate":0.125,"avgChangeRate":-0.126774},{"month":8,"riseRate":0.625,"avgChangeRate":0.065088},{"month":9,"riseRate":0.125,"avgChangeRate":-0.112535},{"month":10,"riseRate":0.125,"avgChangeRate":-0.028187},{"month":11,"riseRate":0.25,"avgChangeRate":-0.102922},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.206123}],"exchange":"NASDAQ","name":"CervoMed","nameEN":"CervoMed"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CervoMed(CRVO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CervoMed,CRVO,CervoMed股票,CervoMed股票老虎,CervoMed股票老虎国际,CervoMed行情,CervoMed股票行情,CervoMed股价,CervoMed股市,CervoMed股票价格,CervoMed股票交易,CervoMed股票购买,CervoMed股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CervoMed(CRVO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}